

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$2.01
Change (%)	▲ 0.04 (2.03%)
Volume	116,992
52 Week Low	\$1.75
Market Cap	\$18,723,114
Rolling EPS	0.14
PE Ratio	14.3571
Shares Outstanding	9,314,982

Data as of 10/17/18 4:00 p.m. ET



Recent Headlines & Events

09/26/18 - 8:00 a.m.
Fibrocell to Present at Upcoming Industry and Investor Conferences

09/25/18 - 8:00 a.m.
Fibrocell Awarded \$1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic

There are currently no events scheduled.

Epidermolysis Bullosa

09/05/18 - 8:00 a.m.

Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma

SEC Filings

Filing Date	Form
10/04/18	8-K
09/25/18	8-K
09/05/18	8-K
08/23/18	4

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	33	10.75	44.1	4,103,191
Mutual Fund	11	.31	1.5	140,555
Director and Officer	1	.01	0.0	3,164

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	1,653,486	17.8	3	06/30/18
Sabby Management, LLC	679,408	7.3	679,408	05/29/18
Anson Funds Management LP.	679,408	7.3	679,408	05/29/18
Intracoastal Capital, L.L.C.	335,466	3.6	335,466	07/11/18
Renaissance Technologies LLC	162,281	1.7	138,742	06/30/18
MSD Partners, L.P.	138,592	1.5	0	06/30/18
The Vanguard Group, Inc.	123,991	1.3	49,262	06/30/18
Heights Capital Management, Inc.	117,099	1.3	117,099	06/30/18
Point72 Asset Management, L.P.	80,000	0.9	0	06/30/18
Creative Planning, Inc.	37,202	0.4	14,984	06/30/18

Data provided by Nasdaq. Minimum 15 minutes delayed.